Press Releases
June 28, 2023
Panbela Announces PACES S0820 Phase III Trial Passes Pre-Planned Futility Analysis
June 26, 2023
Panbela Announces Poster Presentation at the Endocrine Society Meeting
Polyamine Inhibition and β-Cell Preservation in Recent Onset Type 1 Diabetes
View/download poster presentation »
June 21, 2023
Panbela Announces Closing of Approximately $8.5 Million Public Offering
June 16, 2023
Panbela Announces Pricing of Approximately $8.5 Million Public Offering
June 13, 2023
Panbela Announces Sponsored Research Agreement to Evaluate Polyamine Metabolic Inhibitor Therapy in Combination with CAR-T Cell Therapy
June 1, 2023
Panbela Announces Poster Presentation at Immunology of Diabetes Society Meeting
Evaluating the Potential of CPP-1X (Eflornithine) in Recent Onset Type 1 Diabetes
May 31, 2023
Panbela Announces 1-for-30 Reverse Stock Split Effective June 1, 2023
May 22, 2023
Panbela Announces Clinical Trial with Moffitt Cancer Center for Phase I/II Program in STK11 Mutant Non-Small Cell Lung Cancer
May 4, 2023
Panbela Provides Business Update and Reports Q1 2023 Financial Results
April 24, 2023
Panbela to Host First Quarter 2023 Earnings Conference Call on May 4, 2023
Events & Presentations